Cargando…
At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy—Are We Closer to Effective Treatment for Patients?
Among diseases affecting skeletal muscle, muscular dystrophy is one of the most devastating and complex disorders. The term ‘muscular dystrophy’ refers to a heterogeneous group of genetic diseases associated with a primary muscle defect that leads to progressive muscle wasting and consequent loss of...
Autor principal: | Gawlik, Kinga I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983724/ https://www.ncbi.nlm.nih.gov/pubmed/29772730 http://dx.doi.org/10.3390/ijms19051490 |
Ejemplares similares
-
Messenger RNA brings gene editing a step closer to treat muscular dystrophies
por: Jacob, John
Publicado: (2022) -
Gene and Cell Therapy for Muscular Dystrophies: Are We Getting There?
por: Galli, Francesco, et al.
Publicado: (2018) -
Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies
por: Rawls, Alan, et al.
Publicado: (2023) -
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
por: Namgoong, John Hyun, et al.
Publicado: (2016) -
Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)